摘要
Abstract
Objective To investigate the clinic efficacy and prognosis analysis of Xelox on sorafenib drug treating fast advanced primary hepatic cancer. Methods 64 cases failed by simple sorafenib in the hospital from January 2012 to January 2013 were selected. All pa-tients were treated with Xelox regimen. Among them, 50 cases of hepatocellular carcinoma were group A, 10 cases of cholangiocarcinoma were group B, and 4 cases of hepatocellular carcinoma/cholangiocarcinoma were group C. Retrospective analysis was conducted on the clinical and follow-up patient data. The AFP level and HBV DNA changes of patients after treatment of Xelox were recorded, the clin-ic efficacy, adverse reactions and prognosis of the patients were evaluated. Results After treatment, the total control rate of all patients was 84. 38% ( 54/64 );4 cases with hepatitis B, the HBV DNA of were reactivate and returned to normal after antivirus treatment;28 cases ( 43. 75%) had AFP declination. During treatment, the most severe adverse reaction was Ⅰ-Ⅱlevel hand-foot skin reaction ( 12 cases, 18. 75% );besides the liver function lesion improvement after relevant medication, other adverse reactions disappeared a few days after the stop of medication, and were all tolerable adverse reactions. The prognosis of the patients with hepatocellular carcinoma im-proved best, other 2 types were fair, and the difference was not statistic significant ( P > 0. 05 ) . The total meso-position PFS was 5. 84 months, OS meso-position was 11. 94 months. Conclusion Xelox achieves better clinic effect on sorafenib drug treating fast advanced primary hepatic cancer, and the survival rate, life quality are better, which can be seen as a first therapeutic schedule for primary liver cancer.关键词
XELOX方案/索拉菲尼/晚期原发性肝癌/耐药Key words
Xelox scheme/sorafenib/advanced primary hepatic cancer/drug resistance分类
医药卫生
